Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2005-12-06
2005-12-06
Saidha, Tekchand (Department: 1652)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C435S196000, C435S252300, C435S320100, C536S023200, C530S412000
Reexamination Certificate
active
06972124
ABSTRACT:
The present invention provides a highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase and biologically active mutants, fragments and analogs thereof as well as pharmaceutical formulations comprising highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase. The invention also provides methods for treating diseases caused all or in part by deficiencies in human N-acetylgalactosamine-4-sulfatase including MPS VI and methods for producing and purifying the recombinant precursor enzyme to a highly purified form.
REFERENCES:
patent: WO 01/83722 (2001-11-01), None
McGovern et al., J. Biol. Chem. (1982), 257 : 12605-12610.
Brooke et al. et al. Biochimica et Biophysica Acta 1361 (1997) : 203-216.
Anson et al. Biochem. J. (192) 284 : 789-794.
Anson et al., “Correction of Human Mucopolysaccharidosis Type-VI Fibroblasts with Recombinant N-Acetylgalactosamine-4-Sulphatase,”Biochem J., 284:789-794 (1992).
Bielicki et al., “Advantages of Using Same Species Enzyme for Replacement Therapy in a Feline Model of Mucopolysaccharidosis Type VI,”J. Biol. Chem., 274:36335-36343 (1999).
Brooks et al., “Enzyme Replacement Therapy in Mucopolysaccharidosis VI: Evidence for Immune Response S and Alteed Efficacy of Treatment in Animal Models,”Biochem. Biophys. Acta., 1361:203-216 (1997).
Byers et al., “Effect of Enzyme Replacement Therapy on Bone Formation in a Feline Model of Mucopolysaccharidosis Type VI,”Bone, 21:425-431 (1997).
Crawley et al., “Enzyme Replacement Therapy from Birth in a Feline Model of Mucopolysaccharidosis Type VI,”J. Clin. Invest., 99:651-662 (1997).
Crawley et al., “ Enzyme Replacement Therapy from Birth in a Feline Model of Maroteaux-Lamy Syndrome,”J. Clin. Invest., 97:1864-1873 (1996).
Haskins et al., “Spinal Cord Compression and Hindlimb Paresis in Cats with Mucopolysaccharidosis VI,”J. Am. Vet. Med. Assoc., 182:983-985 (1983).
Haskins et al., “The Pathology of the Feline Model of Mucopolysaccharidosis VI,”Am. J. Pathol., 101:657-674 (1980).
Hoogerbrugge et al., “Allogenic Bone Marrow Transplantation for Lysosomal Storage Diseases,”Lancet, 345:1398-1402 (1995).
Inherited Disease, eds., Scriver et al., New York:McGraw Hill, 1989, pp. 1565-1587.
Jezyk et al., “Mucopolysaccharidosis in a Cat with Arysulfatase B Deficiency: A Model of Maroteaux-Lamy Syndrome,”Science, 198:834-836 (1977).
Konde et al., “Radiographically Visualized Skeletal Changes Associated with Mucopolysaccharidosis VI in Cats,”Vet. Radiol., 28:223-228 (1987).
Krivit et al., “Bone-Marrow Transplantation in the Maroteaux-Lamy Syndrome (Mucopolysaccharidosis Type VI),”N. Eng. J. Med., 311:1606-1611 (1984).
Krivit et al., “Maroteaux-Lamy Syndrome—Treatment b, Allogenic Bone Marrow Transplantation in 6 Patients and Potential for Antotransplantation Bone Marrow Gene Insertion,”Intl. Ped., 7:47-52 (1992).
McGovern et al., “Purification and Properties of Feline and Human Arylsulfatase B Isozymes,”J. Biol. Chem., 257:12605-12610 (1982).
Peters et al., “Phylogenetic Conservation of Arylsulfatase,”J. Biol. Chem., 265:3374-3381 (1990).
Roberts et al., “Development of a Procedure for Purification of a Recombinant Therapeutic Protein,”Australasian Biotechnol., 6:93-99 (1996).
Yogalingam et al., “Regulation of N-Acetylglactosamine-4-Sulfatase Expression in Retrovirus-Transduced Feline Mucopolysaccharidosis Type VI Muscle Cells.,”DNA Cell Biol., 18:187-195 (1999).
Chan Wai-Pan
Chen Lin
Fitzpatrick Paul A.
Henstrand John M.
Qin Minmin
BioMarin Pharmaceuticals Inc.
Marshall & Gerstein & Borun LLP
Saidha Tekchand
LandOfFree
Precursor of N-acetylgalactosamine-4-sulfatase, methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Precursor of N-acetylgalactosamine-4-sulfatase, methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Precursor of N-acetylgalactosamine-4-sulfatase, methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3508285